Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review

被引：8

作者：

Tsigkas, Grigorios ^{[1
]}

Vakka, Angeliki ^{[1
]}

Apostolos, Anastasios ^{[1
,2
]}

Bousoula, Eleni ^{[3
]}

Vythoulkas-Biotis, Nikolaos ^{[1
]}

Koufou, Eleni-Evangelia ^{[1
]}

Vasilagkos, Georgios ^{[1
]}

Tsiafoutis, Ioannis ^{[4
]}

Hamilos, Michalis ^{[5
]}

Aminian, Adel ^{[6
]}

Davlouros, Periklis ^{[1
]}

机构：

[1] Univ Hosp Patras, Dept Cardiol, Patras 26504, Greece

[2] Natl & Kapodistrian Univ Athens, Hippocrat Gen Hosp, Dept Cardiol 1, Athens 15772, Greece

[3] Tzaneio Gen Hosp, Dept Cardiol, Piraeus 18536, Greece

[4] Red Cross Hosp, Dept Cardiol 1, Athens 11526, Greece

[5] Heraklion Univ Hosp, Dept Cardiol, Iraklion 71500, Crete, Greece

[6] Ctr Hospitalier Univ Charleroi, Dept Cardiol, B-6042 Charleroi, Belgium

来源：

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE | 2023年 / 10卷 / 04期

关键词：

cancer; acute coronary syndrome (ACS); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); triple antithrombotic therapy (TAT); atrial fibrillation (AF); cardiotoxicity; PERCUTANEOUS CORONARY INTERVENTION; PATENT FORAMEN OVALE; ANTITHROMBOTIC THERAPY; ANTICOAGULANT TREATMENT; ATRIAL-FIBRILLATION; OUTCOMES; DISEASE; CLOSURE; STROKE; BREAST;

D O I：

10.3390/jcdd10040135

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

引用

页数：16

共 50 条

[21] Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI [J].

Wang, Hao-Yu ;

Xu, Bo ;

Song, Chen-Xi ;

Guan, Chang-Dong ;

Xie, Li-Hua ;

Zhao, Yan-Yan ;

Cai, Zhong-Xing ;

Yuan, Sheng ;

Dou, Ke-Fei .

JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2022, 2022

[22] The Bleeding Risk in Antithrombotic Therapies: A Narrative Review [J].

Alatri, Adriano ;

Mazzolai, Lucia .

CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (03) :237-248

[23] Combined antiplatelet therapy and oral anticoagulation: Is a balance between thromboembolism and bleeding possible? [J].

Kuzniatsova, Nadzeya ;

Lip, Gregory Y. H. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 148 (01) :1-3

[24] Toward Optimizing Antiplatelet Therapy for Patients at High Bleeding Risk [J].

Exaire, Jose E. ;

Mixon, Timothy A. .

AMERICAN JOURNAL OF CARDIOLOGY, 2024, 210 :130-132

[25] Bleeding and Mortality With Dual Antiplatelet Therapy The Rashomon Effect [J].

Rao, Sunil V. ;

Harrington, Robert A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (16) :2023-2025

[26] Etiology of gastrointestinal bleeding in patients on dual antiplatelet therapy [J].

Shaukat, Arslan ;

Waheed, Salman ;

Alexander, Ethan ;

Washko, Daniel ;

Dawn, Buddhadeb ;

Olyaee, Mojtaba ;

Gupta, Kamal .

JOURNAL OF DIGESTIVE DISEASES, 2018, 19 (02) :66-73

[27] Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes [J].

Alfredsson, Joakim ;

Neely, Benjamin ;

Neely, Megan L. ;

Bhatt, Deepak L. ;

Goodman, Shaun G. ;

Tricoci, Pierluigi ;

Mahaffey, Kenneth W. ;

Cornel, Jan H. ;

White, Harvey D. ;

Fox, Keith A. A. ;

Prabhakaran, Dorairaj ;

Winters, Kenneth J. ;

Armstrong, Paul W. ;

Ohman, E. Magnus ;

Roe, Matthew T. .

HEART, 2017, 103 (15) :1168-1176

[28] One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients [J].

Pivato, Carlo A. ;

Reimers, Bernhard ;

Testa, Luca ;

Pacchioni, Andrea ;

Briguori, Carlo ;

Musto, Carmine ;

Esposito, Giovanni ;

Piccolo, Raffaele ;

Lucisano, Luigi ;

De Luca, Leonardo ;

Conrotto, Federico ;

De Marco, Andrea ;

Franzone, Anna ;

Presbitero, Patrizia ;

Ferrante, Giuseppe ;

Condorelli, Gerolama ;

Paradies, Valeria ;

Sardella, Gennaro ;

Indolfi, Ciro ;

Condorelli, Gianluigi ;

Stefanini, Giulio G. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (06)

[29] Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk A Cost Consequence Simulation From PARIS [J].

Baber, Usman ;

Leisman, Daniel E. ;

Cohen, David J. ;

Gibson, C. Michael ;

Henry, Timothy D. ;

Dangas, George ;

Moliterno, David ;

Kini, Annapoorna ;

Krucoff, Mitchell ;

Colombo, Antonio ;

Chieffo, Alaide ;

Sartori, Samantha ;

Witzenbichler, Bernhard ;

Steg, Philippe Gabriel ;

Pocock, Stuart J. ;

Mehran, Roxana .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (01) :e004945

[30] Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk [J].

Roffi, Marco ;

Landi, Antonio ;

Heg, Dik ;

Frigoli, Enrico ;

Chalkou, Konstantina ;

Chevalier, Bernard ;

Ijsselmuiden, Alexander J. J. ;

Kastberg, Robert ;

Komiyama, Nobuyuki ;

Morice, Marie-Claude ;

Onuma, Yoshinobu ;

Ozaki, Yukio ;

Peace, Aaron ;

Pyxaras, Stylianos ;

Sganzerla, Paolo ;

Williams, Rupert ;

Xaplanteris, Panagiotis ;

Vranckx, Pascal ;

Windecker, Stephan ;

Smits, Pieter C. ;

Valgimigli, Marco .

JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (22) :2664-2677

← 1 2 3 4 5 →